125 related articles for article (PubMed ID: 17545501)
21. Impact of transformation of negative values and regression models on differences between the UK and US EQ-5D time trade-off value sets.
Augestad LA; Rand-Hendriksen K; Kristiansen IS; Stavem K
Pharmacoeconomics; 2012 Dec; 30(12):1203-14. PubMed ID: 23116290
[TBL] [Abstract][Full Text] [Related]
22. Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An Investigation of the EQ-5D classification system.
Harrison MJ; Davies LM; Bansback NJ; McCoy MJ; Farragher TM; Verstappen SM; Hassell A; Symmons DP
Value Health; 2009 Sep; 12(6):1026-34. PubMed ID: 19473335
[TBL] [Abstract][Full Text] [Related]
23. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
[TBL] [Abstract][Full Text] [Related]
24. A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes.
Sakthong P; Charoenvisuthiwongs R; Shabunthom R
Health Qual Life Outcomes; 2008 Sep; 6():71. PubMed ID: 18811935
[TBL] [Abstract][Full Text] [Related]
25. Responsiveness of EQ-5D utility indices in alcohol-dependent patients.
Günther OH; Roick C; Angermeyer MC; König HH
Drug Alcohol Depend; 2008 Jan; 92(1-3):291-5. PubMed ID: 17888587
[TBL] [Abstract][Full Text] [Related]
26. Assessment of health state in patients with tinnitus: a comparison of the EQ-5D and HUI mark III.
Maes IH; Joore MA; Cima RF; Vlaeyen JW; Anteunis LJ
Ear Hear; 2011; 32(4):428-35. PubMed ID: 21221004
[TBL] [Abstract][Full Text] [Related]
27. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.
Xie F; Li SC; Luo N; Lo NN; Yeo SJ; Yang KY; Fong KY; Thumboo J
Arthritis Rheum; 2007 Aug; 57(6):1043-9. PubMed ID: 17665466
[TBL] [Abstract][Full Text] [Related]
29. Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols.
Henry EB; Barry LE; Hobbins AP; McClure NS; O'Neill C
Value Health; 2020 Jul; 23(7):936-944. PubMed ID: 32762996
[TBL] [Abstract][Full Text] [Related]
30. Differences between hypothetical and experience-based value sets for EQ-5D used in Sweden: Implications for decision makers.
Aronsson M; Husberg M; Kalkan A; Eckard N; Alwin J
Scand J Public Health; 2015 Dec; 43(8):848-54. PubMed ID: 26271493
[TBL] [Abstract][Full Text] [Related]
31. Chinese time trade-off values for EQ-5D health states.
Liu GG; Wu H; Li M; Gao C; Luo N
Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
[TBL] [Abstract][Full Text] [Related]
32. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care.
Shrive FM; Ghali WA; Johnson JA; Donaldson C; Manns BJ
Med Care; 2007 Mar; 45(3):269-73. PubMed ID: 17304086
[TBL] [Abstract][Full Text] [Related]
33. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
Kay S; Ferreira A
Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
[TBL] [Abstract][Full Text] [Related]
34. Estimating EuroQol EQ-5D scores from Population Healthy Days data.
Jia H; Lubetkin EI
Med Decis Making; 2008; 28(4):491-9. PubMed ID: 18556640
[TBL] [Abstract][Full Text] [Related]
35. Measuring health-related utility: why the disparity between EQ-5D and SF-6D?
Bryan S; Longworth L
Eur J Health Econ; 2005 Sep; 6(3):253-60. PubMed ID: 15968563
[TBL] [Abstract][Full Text] [Related]
36. Preference-Based EQ-5D index scores for chronic conditions in the United States.
Sullivan PW; Ghushchyan V
Med Decis Making; 2006; 26(4):410-20. PubMed ID: 16855129
[TBL] [Abstract][Full Text] [Related]
37. The validity of EQ-5D US preference weights in liver transplant candidates and recipients.
Russell RT; Feurer ID; Wisawatapnimit P; Pinson CW
Liver Transpl; 2009 Jan; 15(1):88-95. PubMed ID: 19109831
[TBL] [Abstract][Full Text] [Related]
38. Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample.
Lawrence WF; Fleishman JA
Med Decis Making; 2004; 24(2):160-9. PubMed ID: 15090102
[TBL] [Abstract][Full Text] [Related]
39. Catalogue of EQ-5D scores for the United Kingdom.
Sullivan PW; Slejko JF; Sculpher MJ; Ghushchyan V
Med Decis Making; 2011; 31(6):800-4. PubMed ID: 21422468
[TBL] [Abstract][Full Text] [Related]
40. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
Karlsson JA; Nilsson JÅ; Neovius M; Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2011 Dec; 70(12):2163-6. PubMed ID: 21859684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
